Friday, January 25, 2019
-
Welcome and Keynote Address
Saturday, January 26, 2019
-
EGFR and ALK in the first-, second-, and third-line
-
Overcoming mechanisms of resistance for targeted therapy
-
New oncogenic drivers including ROS1 and BRAF
-
Future targets, such as RET, MET, and HER2
-
Practical applications of immunotherapy
-
I/O as a single-agent or in combination
-
Differences in approaching squamous and nonsquamous NSCLC
-
Fighting immunotherapy resistance pathways
-
Current topics in lung cancer surgery
-
Best practices for radiation therapy in lung cancer
-
I/O and targeted therapies in the neoadjuvant setting
Sunday, January 27, 2019
-
Methods to integrate palliative care
-
The future of lung cancer therapy
-
Immunotherapy beyond PD-(L)1 and CTLA-4
-
What are the new standards for small cell lung cancer?
-
Emerging approaches for mesothelioma
-
Role of I/O for unresectable disease
-
Managing immune-related adverse events
-
Determining biomarkers for checkpoint inhibitors: PD-L1 vs. TMB
-
What are the new standards of care?